Monopar Therapeutics (MNPR) Operating Leases (2022 - 2025)

Monopar Therapeutics' (MNPR) quarterly Operating Leases came in at $154920.0 in Q4 2025, up 118.56% quarter-over-quarter from $70881.0 in Q3 2025.

Monopar Therapeutics (MNPR) Operating Leases (2022 - 2025) Analysis & Trends

Monopar Therapeutics has disclosed Operating Leases across 2 years of filings, most recently posting $154920.0 for Q4 2025.

Operating Leases for Q4 2025 came in at $154920.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $154920.0 (changed N/A YoY), and the FY2025 annual result was $154920.0, changed N/A from the prior year.
Operating Leases came in at $154920.0 for Q4 2025 at Monopar Therapeutics, up from $70881.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $154920.0 in Q4 2025 to a low of $8408.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Monopar Therapeutics	441.25 Mn	441.25 Mn	-

Download Data